Daniel J. DeAngelo, MD, PhD

Dr DeAngelo on the Unique Mechanism of Action of INCA033989 in CALR-Mutated MPNs

March 7th 2025

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of INCA033989 that may address an unmet treatment need for patients with CALR-mutated MPNs.

Dr DeAngelo on the Importance of Consensus Guidelines for Treating Acute Lymphoblastic Leukemia

February 26th 2025

Daniel DeAngelo, MD, PhD, discusses the need for consensus guidelines in the management of ALL, particularly in defining optimal treatment strategies for older adult patients.

Dr DeAngelo on the FDA Approval of Obe-Cel in R/R B-Cell Precursor ALL

January 29th 2025

Daniel DeAngelo, MD, PhD, discusses data supporting the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Dr DeAngelo on the FDA Approval of Blinatumomab Consolidation in CD19+, Ph– B-ALL

January 7th 2025

Daniel DeAngelo, MD, PhD, discusses the FDA approval of blinatumomab in the consolidation phase in CD19-positive, Ph-negative B-cell precursor ALL.

Dr DeAngelo on the Effect of Avapritinib on Bone Density in Advanced Systemic Mastocytosis

January 7th 2025

Daniel DeAngelo, MD, PhD, discusses the effect of avapritinib on bone density in patients with advanced systemic mastocytosis.

Dr DeAngelo on Non-Chemotherapy Treatment Options in CLL

November 15th 2024

Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.

Dr DeAngelo on the Integration of JAK Inhibitors in Myelofibrosis Management

November 11th 2024

Daniel DeAngelo, MD, discusses the integration of JAK inhibitors into clinical practice for patients with myelofibrosis.

Dr DeAngelo on the Evolving Role of JAK Inhibitors in the Management of Myelofibrosis

October 30th 2024

Daniel DeAngelo, MD, PhD, discusses the evolving role of JAK inhibitors in the management of myelofibrosis and highlights remaining unmet needs for this patient population.

Dr DeAngelo on the Current Treatment Paradigm for Myelofibrosis

October 30th 2024

Daniel DeAngelo MD, PhD, discusses current treatment strategies for patients with myelofibrosis, highlighting ongoing and recently presented studies

Dr. DeAngelo on Rates of CRS with Obe-cel in ALL

June 22nd 2022

Daniel J. DeAngelo, MD, PhD, discusses rates of cytokine release syndrome with obecabtagene autoleucel in acute lymphoblastic leukemia.

Dr. DeAngelo on the Exploration of Uproleselan Plus Chemotherapy in R/R AML

March 23rd 2022

Daniel J. DeAngelo, MD, PhD, discusses the exploration of uproleselan plus chemotherapy in relapsed/refractory acute myeloid leukemia.

Unmet Needs in SM Treatment

September 27th 2021

The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.

Chronic Myelomonocytic Cell Leukemia: Clinical Considerations

September 27th 2021

The panel of experts discuss the diagnosis and assessment of chronic myelomonocytic cell leukemia.

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

September 15th 2021

Learn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.

Dr. DeAngelo on the Utility of Moxetumomab Pasudotox in HCL

January 13th 2021

Daniel J. DeAngelo, MD, PhD, discusses the utility of moxetumomab pasudotox-tdfk in hairy cell leukemia.

Dr. DeAngelo on the Mechanism of Action of Pevonedistat in MDS

December 15th 2020

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of pevonedistat in myelodysplastic syndrome.

Dr. DeAngelo on the Utility of Pevonedistat in MDS

July 21st 2020

Daniel J. DeAngelo, MD, PhD, discusses the utility of the investigational agent pevonedistat in myelodysplastic syndrome.

Dr. DeAngelo Discusses Ongoing Trials in AML

February 27th 2018

Daniel J. DeAngelo, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses ongoing trials of patients with acute myeloid leukemia (AML).

Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALL

July 26th 2016